0001104659-26-060299
SEC filingArmata Pharmaceuticals entered into a $25 million secured term loan with Innoviva Strategic Opportunities LLC at 14.0% annual interest, maturing January 11, 2029, to fund advancement of its AP-SA02 Phase 3 program for Staphylococcus aureus bacteremia.
The $25 million secured term loan represents a critical near-term financing event for Armata, whose cash balance declined to $4.8 million as of March 31, 2026 — down from $8.7 million at year-end — amid ongoing clinical development spend. The agreement with Innoviva Strategic Opportunities LLC, Armata’s largest shareholder since 2020, provides non-dilutive capital explicitly earmarked for advancing AP-SA02 into a Phase 3 superiority trial in complicated Staphylococcus aureus bacteremia, expected to initiate in the second half of 2026. Structurally, the loan carries a high 14.0% interest rate and is secured by substantially all company assets, with repayment guaranteed by domestic subsidiaries — signaling both lender confidence and elevated risk transfer. Covenants restrict financial flexibility, including prohibitions on dividends, new debt, and material budget deviations, which may constrain strategic options absent milestone achievements. Financially, Q1 2026 results reflect severe pressure: net loss ballooned to $115.3 million, overwhelmingly driven by a $101.1 million non-cash charge tied to the Convertible Loan’s fair value adjustment — not operational performance. Excluding that item, operating loss was $8.8 million, up modestly from $8.2 million year-over-year, consistent with continued AP-SA02 program execution. Management emphasized FDA Fast Track and QIDP designations for AP-SA02 — which enable rolling BLA review and potential five-year market exclusivity extension — underscoring regulatory tailwinds offsetting near-term liquidity fragility. With no forward guidance disclosed and the loan maturity set for early 2029, investor focus will center on Phase 3 trial initiation timing, FDA engagement progress, and whether additional non-dilutive funding can be secured ahead of anticipated cash exhaustion.